In order to confirm MAGE-A3 is a viable target for T cells, we first checked the expression of MAGE-A3 in two subtypes of NSCLC, lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). This evidence concerns the gene MAGEA3 and squamous cell lung carcinoma.